<code id='33D047D77F'></code><style id='33D047D77F'></style>
    • <acronym id='33D047D77F'></acronym>
      <center id='33D047D77F'><center id='33D047D77F'><tfoot id='33D047D77F'></tfoot></center><abbr id='33D047D77F'><dir id='33D047D77F'><tfoot id='33D047D77F'></tfoot><noframes id='33D047D77F'>

    • <optgroup id='33D047D77F'><strike id='33D047D77F'><sup id='33D047D77F'></sup></strike><code id='33D047D77F'></code></optgroup>
        1. <b id='33D047D77F'><label id='33D047D77F'><select id='33D047D77F'><dt id='33D047D77F'><span id='33D047D77F'></span></dt></select></label></b><u id='33D047D77F'></u>
          <i id='33D047D77F'><strike id='33D047D77F'><tt id='33D047D77F'><pre id='33D047D77F'></pre></tt></strike></i>

          hotspot

          hotspot

          author:leisure time    Page View:216
          he exterior of the U.S. Capitol building is seen at sunrise
          Sarah Silbiger/Getty Images

          WASHINGTON — Panels in both the House and Senate have now passed restrictions to drug middlemen business practices, increasing the chances of those measures being included in future government spending bills.

          The bipartisan reforms to pharmacy benefit managers were among 21 bills that the House Energy & Commerce health subcommittee passed today. The policies are not identical, but at least three PBM reforms have been passed by panels in both chambers:

          advertisement

          • One that would replace PBM fees that are tied to a percentage of drug prices with flat fees
          • Another that would require Medicare to create standard performance measures on which PBMs base pharmacy payments
          • A third that would require PBMs to report a host of information, including drug costs, savings, beneficiary out-of-pocket costs, payments to pharmacies, and the amount of business directed to PBM-owned pharmacies

          The Energy & Commerce subcommittee also passed other bills that mirror legislation that Senate Finance also has passed. That includes legislation to ensure seniors pay no more for drugs than insurers, and a measure that lets insurers add less-expensive biosimilars to formularies mid-year.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more
          OTC birth control: A brief history of over the counter pill design
          OTC birth control: A brief history of over the counter pill design

          Illustration:AlexHogan/STAT;Photo:CourtesyPerrigoIt’snoteverydaythatamarketingteamistaskedwithdesign

          read more
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban

          WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

          read more

          What the cancer research community can learn from the Covid response

          TinaReed,PaulKluetz,JohnOyler,andSolangePetersspeakattheMilkenInstituteFutureofHealthSummit.Screenca